In- Depth Research on AVI Biopharma Inc.

M2 Presswire, April, 2007

M2 PRESSWIRE-11 April 2007-Biotech News: In- Depth Research on AVI Biopharma Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:11042007 In- Depth Research on AVI Biopharma Inc (NASDAQ:AVII) AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense technology.

Its principal products in development target various diseases, including cardiovascular disease and infectious disease. The company's lead product candidate, Resten-NG, is a NEUGENE antisense drug for treating cardiovascular restenosis, or the renarrowing of a coronary artery following angioplasty. AVI BioPharma also conducts a Phase II clinical trial with Resten-NG coupled with its microparticle delivery technology. Its infectious...